The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants

Molecular Cancer Therapeutics

Volumn 12, Issue 11, 2013, Pages 2415-2424

  Medová, Michaela ^a,b   Pochon, Benoît ^a,b   Streit, Bruno ^a,b   Blank Liss, Wieslawa ^a,b   Francica, Paola ^a,b   Stroka, Deborah ^a,b   Keogh, Adrian ^a,b   Aebersold, Daniel M ^a,b   Blaukat, Andree ^c   Bladt, Friedhelm ^c   Zimmer, Yitzhak ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Merck Serono GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 [ 1 [ 3 ( 5 ( 1 METHYLPIPERIDIN 4 YLMETHOXY)PYRIMIDIN 2 YL)BENZYL] 1,6 DIHYDRO 6 OXO PYRIDAZIN 3 YL]BENZONITRILE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; EMD 1214063; HISTIDINE; ISOLEUCINE; LEUCINE; METHIONINE; SCATTER FACTOR RECEPTOR; THREONINE; TYROSINE; UNCLASSIFIED DRUG; VALINE;

AMINO ACID SUBSTITUTION; ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CELL CYCLE G1 PHASE; CELL CYCLE PHASE; CELL LINE; CELL MOTILITY; CELL STRAIN 3T3; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; EFFECTOR CELL; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CELL CYCLE; FEMALE; GENETIC VARIATION; HUMANS; MICE; NEOPLASMS; NIH 3T3 CELLS; PHOSPHORYLATION; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRIDAZINES; PYRIMIDINES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887499021     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Stella GM, Benvenuti S, Comoglio PM. Targeting the MET oncogene in cancer and metastases. Expert Opin Invest Drugs 2010;19: 1381-94.
2. Canadas I, Rojo F, Arumi-Uria M, Rovira A, Albanell J, Arriola E. C-MET as a new therapeutic target for the development of novel anticancer drugs. Clin Transl Oncol 2010;12:253-60.
3. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12: 89-103.
4. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-48.
5. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16:68-73.
6. Sattler M, Reddy MM, Hasina R, Gangadhar T, Salgia R. The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 2011;3:171-84.
7. Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S, Vande Woude GF. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A 1998;95:14417-22.
8. Miller M, Ginalski K, Lesyng B, Nakaigawa N, Schmidt L, Zbar B. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins 2001;44:32-43.
9. Bardelli A, Longati P, Gramaglia D, Basilico C, Tamagnone L, Giordano S, et al. Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proc Natl Acad Sci U S A 1998;95:14379-83.
10. Giordano S, Maffe A, Williams TA, Artigiani S, Gual P, Bardelli A, et al. Different point mutations in the met oncogene elicit distinct biological properties. FASEB J 2000;14:399-406.
11. Graveel CR, London CA, Vande Woude GF. A mouse model of activating Met mutations. Cell Cycle 2005;4:518-20.
12. Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002; 21:4885-93.
13. Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004;23:5387-93.
14. Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS, et al. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer 2008;18:976-84.
15. Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 2005;11:2312-9.
16. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA- 665752. Proc Natl Acad Sci U S A 2006;103:2316-21.
17. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
18. Tamborini E, Pricl S, Negri T, Lagonigro MS, Miselli F, Greco A, et al. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene 2006;25:6140-6.
19. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-7.
20. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-14.
21. Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 2012;9:314-26.
22. Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, et al. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clin Cancer Res 2013; 19:2941-51.
23. Bladt F, Blaukat A, Dorsch D, Fittschen C, Friese-Hamim M, Graedler U, et al. Preclinical characterization of EMD1214063, a potent and highly selective inhibitor of the c-Met kinase in Phase I clinical trials [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AA CR; 2010. Abstract nr 3622.
24. Clinical trials involving HGF/SF-Met inhibitors [cited 2013 Aug 1]. Available from: http://www.vai.org/metclinicaltrials. Trial registration ID (EMD 1204831): NCT01110083. Trial registration ID(EMD1214063): NCT01014936.
25. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 1997;94: 11445-50.
26. Zimmer Y, Vaseva AV, Medova M, Streit B, Blank-Liss W, Greiner RH, et al. Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274. Cancer Lett 2010;289:228-36.
27. Apperley JF Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1116-28.
28. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7: 169-81.
29. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008;47:1025-37.
30. Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Janne PA, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 2011;71:1081-91.
31. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib- resistant tumors. Cancer Res 2010;70:10090-100.
32. Hwang CI, Choi J, Zhou Z, Flesken-Nikitin A, Tarakhovsky A, NikitinAY. MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF. Cell Cycle 2011;10:3834-40.
33. Matsumoto K, Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer 2006;119:477-83.
34. Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 2008;283:2675-83.
35. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-308.
36. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16.
37. Ganapathipillai SS, Medova M, Aebersold DM, Manley PW, Berthou S, Streit B, et al. Coupling of mutated Met variants to DNA repair via Abl and Rad51. Cancer Res 2008;68:5769-77.
38. Medova M, Aebersold DM, Zimmer Y. MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks. Int J Cancer 2012;130:728-34.
39. Medova M, Aebersold DM, Blank-Liss W, Streit B, Medo M, Aebi S, et al. MET inhibition results in DNA breaks and synergistically sensitizes tumor cells to DNA-damaging agents potentially by breaching a damage-induced checkpoint arrest. Genes Cancer 2010;1:1053-62.
40. Humbert M, Medova M, Aebersold DM, Blaukat A, Bladt F, Fey MF, et al. Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. Biochem Biophys Res Commun 2013;431:264-9.
41. Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, Fiscella M, et al. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A 2004;101:17198-203.